Prognostic significance of E-cadherin and N-cadherin expression in Gliomas

Myung-Giun Noh¹, Se-Jeong Oh¹, Eun-Jung Ahn², Yeong-Jin Kim², Tae-Young Jung², Shin Jung², Kyung-Keun Kim³, Jae-Hyuk Lee¹, Kyung-Hwa Lee¹* and Kyung-Sub Moon²*

Abstract

Background: Epithelial-mesenchymal transition (EMT), principally involving an E-cadherin to N-cadherin shift, linked to tumor invasion or metastasis, and therapeutic resistance in various human cancer. A growing body of recent evidence has supported the hypothesis that EMT play a crucial role in the invasive phenotype of gliomas. To evaluate the prognostic connotation of EMT traits in glioma, expression of E-cadherin and N-cadherin was explored in a large series of glioma patients in relation to patient survival rate.

Methods: Expressions of E- and N-cadherin were examined using immunohistochemical analysis in 92 glioma cases diagnosed at our hospital. These markers expressions were also explored in 21 cases of fresh frozen glioma samples and in glioma cell lines by Western blot analysis.

Results: Expression of E-cadherin was observed in eight cases (8.7%) with weak staining intensity in the majority of the immunoreactive cases (7/8). Expression of N-cadherin was identified in 81 cases (88.0%) with high expression in 64 cases (69.5%). Fresh frozen tissue samples and glioma cell lines showed similar results by Western blot analysis. There was no significant difference in either overall survival (OS) or progression-free survival (PFS) according to E-cadherin expression (P > 0.05). Although the OS rates were not affected by N-cadherin expression levels (P = 0.138), PFS increased in the low N-cadherin expression group with marginal significance (P = 0.058). The survival gains based on N-cadherin expression levels were significantly augmented in a larger series of publicly available REMBRANDT data (P < 0.001).

Conclusions: E- and N-cadherin, as representative EMT markers, have limited prognostic value in glioma. Nonetheless, the EMT process in gliomas may be compounded by enhanced N-cadherin expression supported by unfavorable prognostic outcomes.

Keywords: E-cadherin, Epithelial-mesenchymal transition, Glioma, N-cadherin, Prognosis, Survival

Background

Infiltrative tendency is such a prominent feature of malignant gliomas that tumor cells migrate far from the tumoral epicenter through the surrounding parenchyma [1, 2]. In addition to cytological atypia and mitotic activity that are needed for histopathological definition of lower-grade gliomas, microvascular proliferation and/or necrosis are specific defining attributes of glioblastoma, which is the most malignant primary brain tumor [3]. Even lower-grade gliomas assorted as World Health Organization (WHO) grade II to III are characterized by propensity for diffuse infiltration and for the malignant transformation to higher-grade tumors. The hurdle in therapeutic resistance of gliomas is intimately connected to the infiltrative phenotype. The infiltrative feature is an essential part of the clinical aggravation of malignant glioma, making surgical resection incomplete and promoting regrowth of residual tumor cells [1–3]. Infiltrative phenotypes in epithelial
malignancies have been unequivocally linked to the phenomenon of epithelial-mesenchymal transition (EMT) that manifests as tumor recurrence, metastasis and therapeutic intractability [4]. By contrast, only recently has the EMT process in non-epithelial tumors been highlighted as an important player in tumor progression [5–7]. Considering that the various downstream pathways of EMT are related with cancer invasion or metastasis, and therapeutic resistance in non-epithelial human cancer, EMT/EMT-like process can be addressed as a possible therapeutic target [8].

EMT, as a complicated cellular machinery provoked by various circumstantial factors, leads cellular and biochemical acquisition of motile mesenchymal properties from immobile epithelial cells [9]. In recent glioma research, EMT have been named as a key player of tumor progression and invasion. In this respect, the recently defined mesenchymal subgroup of glioblastomas reinforce the idea that the EMT-like process has prognostic consequence for malignant brain tumors [10, 11]. In line with the regulation of stem cell features, EMT may contribute to tumor progression and chemoresistance, and in tumor relapse after treatment as well [8].

Although the contribution of EMT in glioma progression is not as clear as that in epithelial malignancies, glial-mesenchymal transition as a counterpart of EMT has been revealed as an essential process in glioma invasion [12–16]. EMT principally involves an E-cadherin to N-cadherin shift. Still, the clinical impact of E- and N-cadherin including their effect on patient survival rates remains unknown. It is conceivable that expression of E-cadherin and N-cadherin affects the clinical aspect of glioma patients in terms of survival rates. This study assessed the expression of the classic EMT markers in human glioma samples including formalin-fixed paraffin embedded tissues, fresh frozen glioma samples and human and mouse glioma cell lines, and analyzed the implication in the context of patient survival by comparing the data with the statistics from the large cohort NCI Repository for Molecular Brain Neoplasia Database (REMBRANDT).

Methods

Gioma cell lines and human glioma tissue specimens

U118, U87, T98G, U343, and U251 human glioma cell lines were from ATCC (Manassas, VA, USA). The GL261 mouse glioma cell line was a gift from Dr. Maciej S. Lesniak at University of Chicago. All cells were maintained and cultured as described previously [12]. Ninety two glioma specimens were obtained from the patient who underwent surgical resection at Chonnam National University Hwasun Hospital between 2007 and 2012. WHO classification of the central nervous system was used for diagnostic criteria [3]. Frozen samples [N = 20; 8 low-grade (WHO grades I/II) and 12 high-grade (WHO grades III/IV)] were handled as previously described [12]. Samples obtained within 30 min after surgical resection were frozen immediately using liquid nitrogen. The specimens were stored at −80 °C until used. Clinicopathological data were based on the medical records. Radiological findings, such as size and location of tumor, peritumoral edema, and cystic or necrotic changes were obtained from preoperative magnetic resonance imaging (MRI). Overall survival (OS) and progression-free survival (PFS) were determined as previously described [12]. The endpoint of OS was the date of death/the last follow-up visit. The endpoint of PFS was the date of recurrence/progression/death. The Chonnam National University Hwasun Hospital Institutional Review Board approved this study (CNUHH-2016-081), and written informed consent was obtained from patients or their legal surrogates for using resected glioma samples.

Tissue microarray construction and immunohistochemistry

Areas with a high cellularity were selected for tissue microarrays. Immunohistochemical staining was performed as described previously [12]. E-cadherin (1:50 dilution; DAKO, Glostrup, Denmark; Catalogue No. M3612) and N-cadherin (1:500 dilution; Abcam, Cambridge, UK; Catalogue No. ab12221) antibodies were applied into a Bond-max autostainer system (Leica Microsystems, Bannockburn, IL, USA). Antigen retrieval was carried out using citrate buffer at pH 6.0. Negative controls were prepared without using primary antibodies.

All immunostained slides were evaluated twice by two independent observers (NMG and LKH) with no knowledge of the clinical details. E- and N-cadherin immunohistochemistry showed cytoplasmic positivity in glioma cells and sometimes stained the cytoplasmic borders. The intensity of staining was initially classified into 4 grades: 0, no immunoreaction; 1, weak positivity; 2, moderate positivity; and 3, strong reactivity. With N-cadherin staining, cases of grades 0 and 1 positivity were grouped as a low-expression, and cases of grades 2 and 3 as a high-expression for statistical convenience. Two pathologists re-evaluated cases with discordant staining intensity together and made concessions for such cases.

Western blot analysis

Western blot analysis was performed as described [12]. After extraction and quantification of protein
from glioma cells and tissues, proteins (30 μg) were resolved by 10% polyacrylamide gel electrophoresis. The proteins were electrotransferred onto nitrocellulose membranes, blocked by 3% skimmed milk, and followed by sequential incubation with primary antibodies (E-cadherin, 1:500 dilution, mouse host; N-cadherin, 1:500 dilution, rabbit host; Actin, 1:10,000, mouse host, BD Transduction Laboratories, San Jose, CA, USA, Catalogue No. 612656). Protein level was measured by electrochemiluminescence (ECL) system (Pierce Biotechnology, Rockford, IL USA).

Patient datasets and data analysis from REMBRANDT
The past NCI REMBRANDT (used to be at https://cainintegrator.nci.nih.gov/rembrandt/login.do, and currently housed in Georgetown University’s G-DOC System at https://gdoc.georgetown.edu/gdoc/) provided de-identified open data on 343 glioma patients through to May 13, 2014. The correlations between E- or N-cadherin expression and OS were checked in samples from the patients as described previously [12]. The construction of graphs was based on the data according to Affymetrix reporters 219,330 at the Highest Geometric Mean Intensity and related survival. Upregulated, down-regulated, or intermediate group represented ≥2-fold changes in E- or N-cadherin level in comparison with the level of nonglioma samples. Survival differences in groups were estimated by the log-rank test.

Statistical analyses
All data were analyzed with IBM SPSS Statistics program version 23.0 for Window (Armonk, NY, USA), as previously described [12]. For relationships between E- or N-cadherin expression and WHO tumor grades, chi-square test or Fisher’s exact probability test was used. The effect of single variables on OS or PFS was estimated by univariate and multivariate analyses. Cox’s proportional hazards model was applied to find out the independent prognostic factors. A certain variable that could be influenced by other variables, e.g., postoperative adjuvant therapy, was ruled out from the model. The level of significance was set at P < 0.05.

Results
Clinical presentation
This series of 92 cases included 42 male patients (45.7%) and 50 female patients (54.3%). The mean age at the time of histological diagnosis was 47.2 years (range: 2 to 84 years). Fifty eight patients (63.0%) underwent gross total resection and 34 patients (37%) underwent subtotal to partial resection. Forty-four patients (47.8%) received concomitant radiation therapy and chemotherapy. The clinicopathological features of our cases are summarized in Table 1.

Expression of E- and N-cadherin in gliomas
Expression of E- and N-cadherin in gliomas was explored according to WHO tumor grades. E-cadherin expression was observed in eight cases of glioma (Fig. 1a & b). Of 34 low-grade gliomas, three cases showed E-cadherin expression; two cases showed weak expression and one case of subependymal giant cell astrocytoma (SEGA) showed strong expression (Fig. 1b). Five cases out of 58 high-grade gliomas showed E-cadherin immunopositivity, although the staining intensity was weak in all five cases. The correlation between presence of E-cadherin expression and WHO tumor grades (low-grade vs. high-grade) was not significant statistically (P = 0.973, Table 2).

N-cadherin was expressed in the majority of the glioma cases (cases with staining intensity 1 through 3, 81/92, 88.0%, regardless of the staining intensity (Fig. 1c & d). No expression was found in 6 of 58 high-grade gliomas showed E-cadherin immunopositivity, although the staining intensity was weak in all five cases. The correlation between presence of E-cadherin expression and WHO tumor grades (low-grade vs. high-grade) was not significant statistically (P = 0.973, Table 2).

N-cadherin was highly expressed in 64 cases (69.5%). Of 58 high-grade tumors, 17 cases displayed...
low expression of N-cadherin and 41 cases showed high expression. N-cadherin expression was not significantly associated with WHO tumor grades, either ($P = 0.759$).

The expressions of E- and N-cadherin were similarly demonstrated by Western blot analysis in the fresh frozen tissues (Fig. 2). Compared to N-cadherin expression, which was detected in the majority of the glioma samples, the number of cases with E-cadherin expression was much smaller. Also, the positive reaction rates of E- and N-cadherin did not differ significantly according to the tumor grades. Five glioma cell lines including U118, T98G, U343, U251 and GL261 showed N-cadherin expression bands by Western blot analysis.

**OS and PFS**

Median OS of all patients was 44.8 months (95% confidence interval (CI): 37.8–51.8 months). The clinical variables of age and WHO tumor grade were significantly associated with longer survival in univariate analysis (both $P < 0.001$) (Fig. 3, Table 3) and multivariate analysis ($P = 0.002$ and $P = 0.004$, respectively). Smaller tumor size was marginally associated with longer survival by univariate analysis ($P = 0.086$) but did not show statistical significance by multivariate analysis ($P = 0.151$). Sex, location, peritumoral edema, cystic or necrotic change, resection degree and E- and N-cadherin expression were not significantly associated with survival benefit. OS by low

**Table 2** Immunohistochemical expression of E- and N-cadherin in association with WHO tumor grade.

| Marker | Staining intensity | No. (%) | WHO grade |
|--------|-------------------|---------|------------|
|        |                   |         | Low (I-II) | High (III-IV) | $P$ value |
| E-cadherin | 0 | 84 (91.3%) | 31 | 31 (36.9%) | 53 | 53 (63.1%) | 0.973 |
|         | 1 | 7 (7.6%) | 2 | 3 (37.5%) | 5 | 5 (62.5%) |
|         | 2 | 0 (0.0%) | 0 | 0 | 0 | 0 |
|         | 3 | 1 (1.1%) | 1 | 0 | 0 | 0 |
| N-cadherin | 0 | 11 (12.0%) | 5 | 11 (39.3%) | 6 | 17 (60.7%) | 0.759 |
|         | 1 | 17 (18.5%) | 6 | 11 | 11 | 11 |
|         | 2 | 30 (32.6%) | 9 | 23 (35.9%) | 21 | 41 (64.1%) |
|         | 3 | 34 (37.0%) | 14 | 20 | 20 | 20 |
N-cadherin expression was not statistically significant either by univariate analysis or multivariate analysis (both $P > 0.05$). However, patients with low N-cadherin expression showed longer survival than patients with high expression (49.8 months vs. 42.0 months, Fig. 3 and Table 3).

PFS was also analyzed in the context of clinical variables. Similarly to the results of OS analysis, only younger age and lower WHO tumor grades showed statistical significance with relevance to the survival benefit by both univariate and multivariate analyses (Fig. 4 and Table 4, all $P < 0.05$). Interestingly,
smaller tumor size showed significantly longer PFS ($P = 0.046$) and low N-cadherin expression was marginally associated with survival benefit ($P = 0.058$) by univariate analysis, although both variables did not prove to be independent prognostic factors by multivariate analysis ($P = 0.255$ and $P = 0.463$, respectively). Increased PFS gap between the low N-cadherin expression group and high-expression group compared to OS curves are shown in Fig. 4.

Assessment of 343 glioma patients in the REMBRANDT cohort showed that levels of N-cadherin expression were significantly correlated with OS gaps. Comparison between up-regulated or intermediate N-cadherin expression groups and all glioma group showed statistically significant survival differences (Fig. 5; all $P < 0.001$). With up-regulated N-cadherin expression, OS was significantly shortened. However, significant OS gaps were not related to E-cadherin level, similar to our glioma cohort data.

**Discussion**

In the present study, expression of the representative EMT markers, E- and N-cadherin, was investigated in a series of gliomas consisting of WHO grade I through IV tumors to explore the clinical implication with regard to patient survival. Epithelial phenotypes indicated by E-cadherin expression were rarely identified in both low-grade and high-grade tumors, as intuitively expected in non-epithelial malignancies. In comparison, mesenchymal phenotypes denoted by N-cadherin expression were observed in the majority of gliomas through grade I through IV. Although the survival benefit in terms of PFS in the patient group with down-regulated N-cadherin expression showed marginal significance, the survival advantage in the patient group with low N-cadherin expression was increased in the larger REMBRANDT cohort. The current results suggest that the gain of mesenchymal traits in gliomas is boosted by increased N-cadherin expression that is not balanced by E-cadherin alteration.

Glial tumors that lack epithelial phenotypes intrinsically have been observed to rearrange the cytoskeleton, dissimilar to classical EMT of epithelial tumors manifested by E-cadherin to N-cadherin shift [8, 13]. Similar to our data, a prior study reported that the majority of glioblastomas did not show intrinsic E-cadherin expression in a previous study [14]. It has been a very rare occasion to encounter malignant gliomas with E-cadherin expression [17].

Malignant glioma is notable for biological heterogeneity and extreme fatalness, which is fairly

| Characteristics          | No | Mean (months) | $P$-value (univariate) | $P$-value (multivariate) | Hazard ratio |
|--------------------------|----|---------------|------------------------|-------------------------|--------------|
| Age                      |    |               |                        |                         |              |
| <60                      | 63 | 55.4          | <0.001                 | 0.002                   | 1            |
| ≥60                      | 29 | 22.5          |                        |                         | 2.982        |
| Sex                      |    |               |                        |                         |              |
| M                        | 42 | 43.5          | 0.962                  | 0.672                   | 1            |
| F                        | 50 | 44.7          |                        |                         | 0.855        |
| WHO grade                |    |               |                        |                         |              |
| Low (I-II)               | 34 | 60.7          | <0.001                 | 0.004                   | 1            |
| High (III-IV)            | 58 | 34.2          |                        |                         | 4.016        |
| Tumor size               |    |               |                        |                         |              |
| <4.5                     | 49 | 50.0          | 0.086                  | 0.151                   | 1            |
| ≥4.5                     | 43 | 37.8          |                        |                         | 1.752        |
| Location                 |    |               |                        |                         |              |
| Non-eloquent area        | 45 | 31.7          | 0.141                  | 0.487                   | 1            |
| Near eloquent area       | 47 | 38.4          |                        |                         | 1.290        |
| Edema                    |    |               |                        |                         |              |
| None/minimal             | 42 | 35.6          | 0.581                  | 0.280                   | 1            |
| Moderate/severe          | 50 | 34.4          |                        |                         | 0.675        |
| Cystic change            |    |               |                        |                         |              |
| None                     | 40 | 37.5          | 0.941                  | 0.870                   | 1            |
| Present                  | 52 | 34.6          |                        |                         | 1.062        |
| Resection degree         |    |               |                        |                         |              |
| Partial/subtotal         | 34 | 33.6          | 0.959                  | 0.455                   | 1            |
| Gross total              | 58 | 36.8          |                        |                         | 1.303        |
| E-cadherin               |    |               |                        |                         |              |
| No                       | 84 | 45.4          | 0.585                  | 0.780                   | 1            |
| Positive                 | 8  | 21.5          |                        |                         | 1.181        |
| N-cadherin               |    |               |                        |                         |              |
| Low                      | 28 | 49.8          | 0.138                  | 0.456                   | 1            |
| High                     | 64 | 42.0          |                        |                         | 1.362        |
connected to its infiltrative attribute. [1, 2]. EMT is a crucial component in early developmental course, tissue repair process and restructuring [18], and takes an important part of tumor advancement [19] and metastasis [4]. Certain transcription factors such as Slug, Snai1, Twist and matrix metalloproteinases, have been reported to be implicated in EMT, and to promote glioma cell migration and invasion [19–22]. Epithelial cell plasticity is rigorously redirected to display increased mesenchymal cadherins including N-cadherin or cadherin-11 and to convert immotile parent epithelial cells to motile cells with enhanced invasive properties [23, 24].

In cancerous transformations, the acquisition of EMT traits is closely linked to the proceeding of dedifferentiation and gain of stem cell status [4]. As supported by important experimental findings in epithelial malignancies including colon, pancreatic and breast cancer, induction of EMT can co-induce stem cell properties, thereby connecting cell motility and stem cell-like programs [4, 25, 26]. Malignant gliomas turned out to have cancer stem cell population recently [27]. However, the co-existence of stem cell and EMT features during the progression of glioblastoma has been described lately [9]. Aside from metastasis, which is rare in gliomas, dedifferentiated phenotype in the residual tumor cell population at the invasive front is coupled with malignant transformation in the recurrent tumor. Despite removal of extensive tumor volume based on grossly detectable levels, microscopic foci of remnant tumor cells beyond the resection margins bring about eventual tumor recurrence, not infrequently accompanied by advance into a higher-grade glioma. With the most infiltrative phenotype of the cells in the invasion front far off the resection margins, the tumor cells are prone to proliferate and to progress after a variable dormant period by means of stem cell characteristics in the remaining population. A previous study reported the enhanced expression of stem cell factors

Fig. 4 Kaplan–Meier estimates of progression-free survival according to age, tumor grades and E- and N-cadherin expression level. Age ($P < 0.001$) and WHO tumor grade ($P < 0.001$) showed statistically significance. Expression of N-cadherin was related with progression-free survival of glioma patients with marginal statistical significance
in paired primary and recurrent glioma samples by unsupervised clustering analysis of gene expression profiling [28]. The concurrence of a stem cell status with EMT features in glioblastoma, either via the β-catenin pathway or KITENIN mediation, has been recently described [12, 13].

Increased mesenchymal traits are considered to be a pivotal molecular event that leads to enhanced malignancy in gliomas [8]. Based on genome-scale analysis of large cohorts of glioblastomas, four different subgroups were identified that are dependent on neural differentiation [10, 11]. Glioblastomas categorized into the mesenchymal subtype displayed by far shorter overall and progression-free survival periods, related with extensive aggressiveness indicated by multifocality or therapeutic resistance against radio- and chemo-therapy [11]. Accordingly, the clinical consequence of invasive phenotype induced by EMT is evident. A previous study proposed that a small population of glioma cells undergo molecular events that bring about cytoskeletal reorganization and apoptotic resistance. As a result, the tumor cells become highly motile and invasive and then evolve into the treatment-resistant condition [8]. Compared to metastases of most carcinomas in which the eventual process recapitulate the organization of the primary tumors [29], the evolutionary changes in glioma progression do not involve the organization represented by restoration of E-cadherin expression. Instead, glioma progression seems to incorporate strengthened mesenchymal phenotypes in relevance to up-regulated N-cadherin expression and resultant therapeutic resistance. In addition, glioblastoma clusters other than the mesenchymal subtype acquire mesenchymal traits over recurrent episodes [11]. An evolutionary change with increased mesenchymal phenotype appears to be a frequent episode with regard to disease progression, alike cancer cells using EMT mechanism during the advance to a more aggressive status [8, 30]. However, further investigation needs be performed to reveal the relation between N-cadherin or other EMT markers/inducers and key parameters for new 2016 WHO glioma classification, such as IDH1 mutation, 1p/19q co-deletion or MGMT promoter methylation [31].

**Conclusions**

The present study shows that E- and N-cadherin expressions in glioma have limited value as a survival predictor. However, N-cadherin expression showed prognostic implication with marginal significance in our glioma cohort and by far more significant

| Characteristics     | No | Mean (months) | P-value (univariate) | P-value (multivariate) | Hazard ratio |
|---------------------|----|---------------|----------------------|------------------------|--------------|
| Age                 |    |               |                      |                        |              |
| <60                 | 63 | 47.0          | <0.001               | 0.002                  | 1            |
| ≥60                 | 29 | 13.4          | 0.623                | 0.632                  | 1            |
| Sex                 |    |               |                      |                        |              |
| M                   | 42 | 33.1          | 0.046                | 0.255                  | 1            |
| F                   | 50 | 38.1          | 0.145                | 0.775                  | 1            |
| WHO grade           |    |               |                      |                        |              |
| Low (I-ll)          | 34 | 58.8          | <0.001               | <0.001                 | 1            |
| High (ll-Iv)        | 58 | 22.7          | 0.549                | 0.913                  | 1            |
| Tumor size          |    |               |                      |                        |              |
| <4.5                | 49 | 43.0          | 0.046                | 0.255                  | 1            |
| ≥4.5                | 43 | 28.4          | 0.549                | 0.913                  | 1            |
| Location            |    |               |                      |                        |              |
| Non-eloquent area   | 45 | 42.3          | 0.046                | 0.255                  | 1            |
| Near eloquent area  | 47 | 44.1          | 0.800                | 0.794                  | 1            |
| Edema               |    |               |                      |                        |              |
| None/minimal        | 42 | 41.4          | 0.046                | 0.255                  | 1            |
| Moderate/severe     | 50 | 45.0          | 0.046                | 0.255                  | 1            |
| Cystic change       |    |               |                      |                        |              |
| None                | 40 | 45.8          | 0.840                | 0.954                  | 1            |
| Present             | 52 | 42.1          | 0.840                | 0.954                  | 1            |
| Resection degree    |    |               |                      |                        |              |
| Partial/subtotal    | 34 | 42.8          | 0.746                | 0.473                  | 1            |
| Gross total         | 58 | 44.4          | 0.746                | 0.473                  | 1            |
| E-cadherin          |    |               |                      |                        |              |
| No                  | 28 | 46.5          | 0.654                | 0.838                  | 1            |
| Positive            | 64 | 31.7          | 0.654                | 0.838                  | 1            |
| N-cadherin          |    |               |                      |                        |              |
| Low                 | 68 | 38.2          | 0.038                | 0.463                  | 1            |
| High                | 24 | 24.9          | 0.038                | 0.463                  | 1            |
The EMT process accompanied by enhanced N-cadherin expression may contribute to the biological aggressiveness in glioma by increased mesenchymal phenotype that is supported by variably unfavorable prognostic outcome.

Abbreviations
EMT: Epithelial-mesenchymal transition; IHC: Immunohistochemistry; MRI: Magnetic resonance imaging; OS: Overall survival; PFS: Progression-free survival

Acknowledgements
Not applicable.

Funding
This work was supported by Chonnam National University Hospital Biomedical Research Institute (HCR14024-1, HCR15014-21), partly by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Minister of Education (2016R1A2B1014597, 2016R1C1B2007494). There was no role of the funding bodies in the design of the study, in collection, analysis, and interpretation of data or in writing the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
KHL and KSM designed this study. MGN, SJO and EJA carried out the experimental studies. MGN, KHL and KSM drafted the manuscript. KHL and KSM carried out the statistical analysis. YJK, TYJ, SJK, KKK and JHL carried out the interpretation of clinical and experimental data. YJK, TYJ, SJK, KKK and JHL revised the manuscript for critical points. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the institutional review board of the Chonnam National University Hwasun Hospital (CHUHHE-2016-081), and all the patients...
provided written informed consent for the use of clinical specimens for medical research.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Pathology, Chonnam National University Hwasun Hospital and Medical School, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 519-763, South Korea. 2Department of Neurosurgery, Chonnam National University Hwasun Hospital and Medical School, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 519-763, South Korea. 3Medical Research Center of Gene Regulation and Center for Creative Biomedical Scientists, Chonnam National University Medical School, Gwangju, South Korea.

Received: 7 March 2017 Accepted: 22 August 2017
Published online: 29 August 2017

References
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.

2. Rouseau A, Mokhtar K, Duyckaerts C. The 2007 WHO classification of tumors of the central nervous system - what has changed? Curr Opin Neurol. 2008;21(6):720–7.

3. Kleihues P, Louis DN, Wiestler OD, Burger PC, Scheithauer BW. WHO grading of tumours of the central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. Classification of tumours of the central nervous system. 4th ed. Lyon: International Agency for Research on Cancer; 2007. p. 10–1.

4. Brabletz T. To differentiate or not—routes towards metastasis. Nat Rev Cancer. 2012;12(6):425–36.

5. Nagaiishi M, Paulus W, Brokinkel B, Vital A, Tanaka Y, Nakazato Y, Giangaspero F, Ohgaki H. Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma. Brain Pathol. 2012;22(5):670–6.

6. Guo Y, Xi, Z, Koontz Z, Kim A, Xie J, Gorlick R, Hoang BH. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res. 2007;25(7):964–71.

7. Costes E, Hamdan G, Jeanpierre S, Voeltzel T, Sagoyou K, Hayes S, Mahon FX, Dumontet C, Puisieux A, Nicoli FE, Maguer-Satta V. Deregelation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood. 2011;117(5):1673–6.

8. Kahler UD, Nishikawa G, Maciacyz J. Epithelial-to-mesenchymal (−like) transition as a relevant molecular event in malignant gliomas. Cancer Lett. 2013;331(2):131–8.

9. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8.

10. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Sorocoeau L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subcellulars of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157–73.

11. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Willerman MD, Miller CR, Ding L, Golub T, Mesirov JP, Alleva G, Lawrence M, O’Kelly M, Tamayo P, Wei BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feifer HS, Hodgson JD, James CD, Sarkaria JN, Brennan C, Akin A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):88–110.

12. Lee KH, Ahn EJ, Oh SJ, Kim O, Joo YE, Bae JA, Yoon S, Ryu HH, Jung S, Kim KK, Lee JH, Moon KS. KIT and its activity and expression in schwannoma - a case report. Cancer Cell. 2010;9:194.

13. Qi S, Song Y, Peng Y, Wang H, Long H, Yu X, Li Z, Fang L, Wu A, Luo W, Zhen Y, Zhou Y, Chen Y, Mai C, Liu Z, Fang W, ZEB1 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One. 2012;7(6):e38842.

14. Mikheeva SA, Mikheev AM, Petkova T, Bauer J, Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, Gonzalez-Herrero I, Sanchez-Garcia I, Silber JR, Horner PJ, Rostomily RC. TWIST1 promotes invasion through mesenchymal-epithelial transformation in human glioblastoma. Mol Cancer. 2010;9:194.

15. Kalluri R, Weinberg EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112(12):1776–84.

16. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):424–52.

17. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118(3):277–9.

18. Qiao B, Johnson NW, Gao J. Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta1 in small family-dependent and correlates with matrix metalloproteinase-2 and -9 expressions. Int J Oncol. 2010;37(3):635–68.

19. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15(2):101–12.

20. Tran NL, Nagle RB, Cress AE, Heimark RL, N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with Stromal cells. Am J Pathol. 1999;155(3):787–98.

21. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–37.

22. Morel AP, Lieve M, Thomas C, Hinkel G, Ansiau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008;3(8):e2888.

23. Mani SA, Guo W, Liao MJ, Eaton AE, Ayyanan A, Zou HY, Brooks M, Reinhard F, Zhang CC, Shipston M, Campbell LL, Polyak K, Brink E, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;13(4):704–15.

24. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.

25. Kwon SM, Kang SH, Park CK, Jung S, Park ES, Lee JS, Kim SH, Woo HG. Recurrent glioblastomas reveal molecular subtypes associated with mechanistic implications of drug-resistance. PLoS One. 2015;10(10):e0140528.

26. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating glioblastoma stem cells - an integrated concept of malignant tumour progression initiating cells. Nat Rev Cancer. 2005;5(9):744–9.

27. Iwadate Y. Epithelial-mesenchymal transition in glioblastoma progression. Oncol Lett. 2016;11(3):1615–20.

28. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, D'haeseleer D, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.